ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-infectious Anterior Uveitis
Conditions
Non-infectious Anterior Uveitis
Trial Timeline
Apr 26, 2017 → Apr 26, 2019
NCT ID
NCT03131154About ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution
ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution is a phase 3 stage product being developed by Aldeyra Therapeutics for Non-infectious Anterior Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03131154. Target conditions include Non-infectious Anterior Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03131154 | Phase 3 | Completed |
Competing Products
10 competing products in Non-infectious Anterior Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Adalimumab | AbbVie | Approved | 85 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| FAI insert + Sham injection | EyePoint Pharmaceuticals | Phase 3 | 72 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 72 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |
Other Products from Aldeyra Therapeutics
Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BIDPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3
69